← All organizations
Loxo Oncology
For profitContributed to NME
Also known as: LOXO ONCOL | Loxo Oncology | LOXO Oncology | Loxo Oncology, Inc. | LOXO ONCOLOGY INC | Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company | Loxo Oncology Medical Monitor, VP of R&D | Senior Medical Director, Loxo Oncology
Highest phase reached
Phase 3
First clinical trial
Apr 1, 2014First marketed drug
Nov 26, 2018First NDA
Nov 26, 2018Last known activity
Nov 30, 2024
Acquired by Eli Lilly on Jan 7, 2019
Timeline
2010s
- Jul 1, 2010
Loxo Oncology— Founded
- Nov 26, 2018
larotrectinib— NDA Organization
- Jan 7, 2019
Eli Lilly— Acquired By
2020s
- Jan 27, 2023
pirtobrutinib— Marketing Organization
Drugs by trial phase (54 distinct, 72 trials)
Phase 3 (16 own, 0 via acquisition)
Phase 2 (7 own, 0 via acquisition)
Phase 1 (30 own, 0 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Approved for
Studied for
- Brain Stem Neoplasms
- Carcinoma, Neuroendocrine
- Carcinoma, Non-Small-Cell Lung
- Central Nervous System Neoplasms
- Cholangiocarcinoma
- Chondrosarcoma
- Colonic Neoplasms
- Fibrosarcoma
- Glioma
- Hematologic Neoplasms
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myeloid, Acute
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myelomonocytic, Juvenile
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, B-Cell, Marginal Zone
- Lymphoma, Mantle-Cell
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Myofibromatosis
- Neoplasms
- Nervous System Neoplasms
- Preleukemia
- Sarcoma
- Thyroid Cancer, Papillary
- Thyroid Diseases
- Thyroid Neoplasms
- Waldenstrom Macroglobulinemia
Marketed drugs (3)
Recent trials (50)
- NCT03206931Lead sponsorN/A—
- NCT03206931Study directorN/A—
- NCT05225259CollaboratorN/A—
- NCT05172700Lead sponsorN/A—
- NCT03906331Study directorN/A—
- NCT05225259Study directorN/A—
- NCT03906331Lead sponsorN/A—
- NCT06588478Lead sponsorPhase 2Nov 30, 2024
- NCT06333262CollaboratorPhase 2Apr 22, 2024
- NCT06119581CollaboratorPhase 3Jan 3, 2024
- NCT06104683Lead sponsorPhase 2Nov 1, 2023
- NCT06111521Study directorPhase 1Oct 27, 2023
- NCT06111521CollaboratorPhase 1Oct 27, 2023
- NCT06102512Study directorPhase 1Oct 23, 2023
- NCT06102512CollaboratorPhase 1Oct 23, 2023
Details
- Founded
- Stamford, CT, US Jul 1, 2010
- First NDA
- Nov 26, 2018
- Last known activity
- Nov 30, 2024
Designations held
- Orphan drug
- Priority review
- Breakthrough therapy
- Accelerated approval